Stemina awarded third Phase I SBIR
Stemina was awarded its third Phase I SBIR today. The study, entitled “Identification of Biomarkers of Cardiotoxicity Using Metabolomics Analysis on Human Pluripotent Stem Cell-Derived Cardiomyocytes,” was funded by the National Institute of General Medical Sciences. The purpose of this study is to alleviate the financial burden of compound attrition due to cardiotoxicity and to improve public health through the development of an in vitro assay to predict a drug’s ability to induce cardiotoxicity. Cardiac safety is one of the leading causes of compound attrition in the pharmaceutical industry and withdrawal of FDA-approved drugs from the market.